Pulmonary toxicity of polysorbate-80-coated inhalable nanoparticles; In vitro and in vivo evaluation

AAPS Journal

Volumn 12, Issue 3, 2010, Pages 294-299

  Al Hallak, M H D Kamal ^a,b   Azarmi, Shirzad ^a,c   Sun, Chris ^d   Lai, Patrick ^d   Prenner, Elmar J ^d   Roa, Wilson H ^a   Löbenberg, Raimar ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DAMASCUS UNIVERSITY   (Syrian Arab Republic)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

inhalable nanoparticles; polysorbate 80; pulmonary toxicity; surface pressure area isotherm

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; NANOPARTICLE; POLYSORBATE 80; POLYSORBATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FILM; IN VITRO STUDY; IN VIVO STUDY; LUNG TOXICITY; MOUSE; NONHUMAN; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; NUDE MOUSE; TOXICITY;

ADMINISTRATION, INHALATION; ANIMALS; LUNG; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; POLYSORBATES; IN VITRO TECHNIQUES;

EID: 77955978148     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9190-4     Document Type: Article

References (20)

1. S Azarmi WH Roa R Lobenberg 2008 Targeted delivery of nanoparticles for the treatment of lung diseases Adv Drug Deliv Rev 60 8 863 875 10.1016/j.addr.2007.11.006 1:CAS:528:DC%2BD1cXlslagu70%3D 18308418
2. G Oberdorster 2001 Pulmonary effects of inhaled ultrafine particles Int Arch Occup Environ Health 74 1 1 8 10.1007/s004200000185 1:CAS:528: DC%2BD3cXotVSktro%3D 11196075
3. G Oberdorster E Oberdorster J Oberdorster 2005 Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles Environ Health Perspect 113 7 823 839 10.1289/ehp.7339 1:CAS:528:DC%2BD2MXntVyls7Y%3D 16002369
4. C Muhlfeld B Rothen-Rutishauser F Blank D Vanhecke M Ochs P Gehr 2008 Interactions of nanoparticles with pulmonary structures and cellular responses Am J Physiol Lung Cell Mol Physiol 294 5 817 829 10.1152/ajplung.00442.2007
5. SM Moghimi AC Hunter JC Murray 2001 Long-circulating and target-specific nanoparticles: theory to practice Pharmacol Rev 53 2 283 318 1:CAS:528:DC%2BD3MXkt1Gnurc%3D 11356986
6. L Illum PD Jones RW Baldwin SS Davis 1984 Tissue distribution of poly(hexyl 2-cyanoacrylate) nanoparticles coated with monoclonal antibodies in mice bearing human tumor xenografts J Pharmacol Exp Ther 230 3 733 736 1:CAS:528:DyaL2cXlslOnsbo%3D 6590835
7. L Araujo R Lobenberg J Kreuter 1999 Influence of the surfactant concentration on the body distribution of nanoparticles J Drug Target 6 5 373 385 10.3109/10611869908996844 1:CAS:528:DyaK1MXjtlCgsLw%3D 10342385
8. SM Moghimi AC Hunter 2001 Capture of stealth nanoparticles by the body's defences Crit Rev Ther Drug Carrier Syst 18 6 527 550 1:CAS:528: DC%2BD38XlvFCrsA%3D%3D 11789674
9. RN Alyaudtin A Reichel R Lobenberg P Ramge J Kreuter DJ Begley 2001 Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro J Drug Target 9 3 209 221 10.3109/10611860108997929 1:CAS:528:DC%2BD3MXmt12rtrw%3D 11697206
10. T Ku S Gill R Lobenberg S Azarmi W Roa EJ Prenner 2008 Size dependent interactions of nanoparticles with lung surfactant model systems and the significant impact on surface potential J Nanosci Nanotechnol 8 6 2971 2978 10.1166/jnn.2008.171 1:CAS:528:DC%2BD1cXotlKku7o%3D 18681033
11. S Gill R Lobenberg T Ku S Azarmi W Roa EJ Prenner 2007 Nanoparticles: characteristics, mechanisms of action, and toxicity in pulmonary drug delivery-a review J Biomedl Nanotech 3 2 107 119 10.1166/jbn.2007.015 1:CAS:528: DC%2BD2sXmvF2rtLw%3D
12. FB Smith 1983 Role of the pulmonary surfactant system in lung diseases of adults N Y State J Med 83 6 851 856 1:STN:280:DyaL3s3ksFKktQ%3D%3D 6575291
13. WR Schief M Antia BM Discher SB Hall V Vogel 2003 Liquid crystalline collapse of pulmonary surfactant monolayers Biophys J 84 6 3792 3806 10.1016/S0006-3495(03)75107-8 1:CAS:528:DC%2BD3sXksVKns7s%3D 12770885
14. D Stuart R Lobenberg T Ku S Azarmi L Ely W Roa, et al. 2006 Biophysical investigation of nanoparticle interactions with lung surfactant model systems J Biomed Nanotech 2 2-3 245 252 10.1166/jbn.2006.031 1:CAS:528: DC%2BD2sXisV2qug%3D%3D
15. S Azarmi R Lobenberg WH Roa S Tai WH Finlay 2008 Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles Drug Dev Ind Pharm 34 9 943 947 10.1080/03639040802149079 1:CAS:528:DC%2BD1cXhtFais7%2FI 18800255
16. JO Sham Y Zhang WH Finlay WH Roa R Lobenberg 2004 Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung Int J Pharm 269 2 457 467 10.1016/j.ijpharm.2003.09.041 1:CAS:528:DC%2BD3sXhtVWjsrzJ 14706257
17. S Azarmi X Tao H Chen Z Wang WH Finlay R Lobenberg, et al. 2006 Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles Int J Pharm 319 1-2 155 161 10.1016/j.ijpharm.2006.03.052 1:CAS:528:DC%2BD28XmvFKgu7g%3D 16713150
18. C Vauthier D Labarre G Ponchel 2007 Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery J Drug Target 15 10 641 663 10.1080/10611860701603372 1:CAS:528:DC%2BD2sXhtlClsrzL 18041633
19. DM Brown MR Wilson W MacNee V Stone K Donaldson 2001 Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines Toxicol Appl Pharmacol 175 3 191 199 10.1006/taap.2001.9240 1:CAS:528:DC%2BD3MXmsl2nu7o%3D 11559017
20. M Kodama O Shibata S Nakamura S Lee G Sugihara 2004 A monolayer study on three binary mixed systems of dipalmitoyl phosphatidyl choline with cholesterol, cholestanol and stigmasterol Colloids Surf B Biointerfaces 33 3-4 211 226 10.1016/j.colsurfb.2003.10.008 1:CAS:528:DC%2BD2cXptFWmug%3D%3D